These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17723180)

  • 1. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms.
    Raina K; Agarwal R
    Acta Pharmacol Sin; 2007 Sep; 28(9):1466-75. PubMed ID: 17723180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK; Singh RP; Agarwal C; Chan DC; Agarwal R
    Clin Cancer Res; 2002 Nov; 8(11):3512-9. PubMed ID: 12429642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
    Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
    Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
    Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death.
    Dhanalakshmi S; Agarwal P; Glode LM; Agarwal R
    Int J Cancer; 2003 Sep; 106(5):699-705. PubMed ID: 12866029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study.
    Li WG; Wang HQ
    J BUON; 2016; 21(4):917-924. PubMed ID: 27685914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells.
    Tyagi AK; Agarwal C; Chan DC; Agarwal R
    Oncol Rep; 2004 Feb; 11(2):493-9. PubMed ID: 14719089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
    Singh RP; Sharma G; Dhanalakshmi S; Agarwal C; Agarwal R
    Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):933-9. PubMed ID: 14504208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
    Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
    Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
    Li Y; Ahmed F; Ali S; Philip PA; Kucuk O; Sarkar FH
    Cancer Res; 2005 Aug; 65(15):6934-42. PubMed ID: 16061678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
    Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
    Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting silibinin in the antiproliferative pathway.
    Li L; Zeng J; Gao Y; He D
    Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.
    Bosch-Barrera J; Menendez JA
    Cancer Treat Rev; 2015 Jun; 41(6):540-6. PubMed ID: 25944486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
    Agarwal C; Singh RP; Dhanalakshmi S; Tyagi AK; Tecklenburg M; Sclafani RA; Agarwal R
    Oncogene; 2003 Nov; 22(51):8271-82. PubMed ID: 14614451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 16. Silibinin induces apoptosis and inhibits proliferation of estrogen receptor (ER)-negative breast carcinoma cells through suppression of nuclear factor kappa B activation.
    Yousefi M; Ghaffari SH; Zekri A; Hassani S; Alimoghaddam K; Ghavamzadeh A
    Arch Iran Med; 2014 May; 17(5):366-71. PubMed ID: 24784867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
    Singh RP; Agarwal R
    Mutat Res; 2004 Nov; 555(1-2):21-32. PubMed ID: 15476849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells.
    Zhou L; Liu P; Chen B; Wang Y; Wang X; Chiriva Internati M; Wachtel MS; Frezza EE
    Anticancer Res; 2008; 28(2A):1119-27. PubMed ID: 18507063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
    Vadgama JV; Wu Y; Shen D; Hsia S; Block J
    Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting STAT3 with silibinin to improve cancer therapeutics.
    Bosch-Barrera J; Queralt B; Menendez JA
    Cancer Treat Rev; 2017 Jul; 58():61-69. PubMed ID: 28686955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.